Envu reports psoriasis and lupus trial efficacy; NDA on track
Envu says it demonstrated strong efficacy and safety in psoriasis and promising results in biomarker-positive lupus, and that its NDA filing remains on track for Q4.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.